Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan

Masaaki Niino, Toshiyuki Fukazawa, Jun-ichi Kira, Tatsusada Okuno, Masahiro Mori, Nobuo Sanjo, Takashi Ohashi, Hikoaki Fukaura, Juichi Fujimori, Yuku Shimizu, Nobuhiro Mifune, Yusei Miyazaki, Eri Takahashi, Seiji Kikuchi, Dawn Langdon, Ralph HB Benedict and Makoto Matsui

Abstract
Background: The Brief International Cognitive Assessment for MS (BICAMS) is a practical battery for measuring cognitive function in multiple sclerosis (MS).
Objectives: We aimed to validate a Japanese version of the BICAMS in patients with MS and healthy controls.
Methods: The Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-Second Edition (CVLT2) and the Brief Visuospatial Memory Test Revised (BVMTR) were administered to 156 patients with MS and 126 healthy controls (HCs). The BICAMS was re-administered in a subset of 27 MS patients and 30 HCs.
Results: The mean (±SD) raw scores in the MS and HC groups were as follows: SDMT: MS 47.9±14.0, HC 61.0±9.5; CVLT2: MS 48.6±12.6, HC 55.7±10.5; BVMTR: MS 23.5±8.4, HC 28.3±5.4, respectively, and significant differences were found between the two groups on all tests (p<0.0001). Cohen’s d values were 1.07, 0.60, and 0.67 in SDMT, CVLT2, and BVMTR, respectively. The test-retest reliability coefficients for each test were as follows: SDMT: r=0.93; CVLT2: r=0.82; and BVMTR: r=0.77 (p<0.0001).
Conclusions: This study provides results that support the reliability and validity of the BICAMS in Japan.

Keywords: Multiple sclerosis, cognition, BICAMS, validity, neuropsychology, Japanese

Date received: 4 September 2017; revised 27 November 2017; accepted: 27 November 2017

Introduction
Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system (CNS), and a progressive, neurodegenerative course is common, as represented by decline in clinical metrics and progressive brain atrophy. While physical disability as evaluated by the Expanded Disability Status Scale (EDSS) remains the most commonly applied clinical outcome in MS, attention to cognitive function in MS is increasing. There is modest correlation between EDSS score and cognitive abilities assessed via neuropsychological testing. However, cognitive impairment tends to progress over time, sometimes independently of the accumulation of physical disability. Despite cognitive tests having been validated in MS, a neuropsychological evaluation is not routinely implemented alongside EDSS scoring. In fact, 25% of patients with an EDSS score of less than 4.0 have cognitive impairment that is not captured by the EDSS alone.

In general, neuropsychological studies suggest that 40–65% of patients with MS are cognitively impaired. Most often cognitive processing speed (CPS) and memory are involved. The Minimal Assessment of Cognitive Function in MS (MACFIMS) was the first effort to develop consensus on an optimal neuropsychological test battery for patients with MS. The MACFIMS requires at least 90 min of face-to-face examination, preferably with...
board-certified neuropsychologists or well-trained technicians. In 2012, a panel of experts was convened to improve the accessibility of neuropsychological testing in MS centers by narrowing the focus of the battery to only tests of CPS and new learning. The resulting Brief International Cognitive Assessment for MS (BICAMS) was designed for potential international use, as the components are easily translated. The BICAMS includes the Symbol Digit Modalities Test (SDMT), the second edition of the California Verbal Learning Test (CVLT2) and the revised Brief Visuospatial Memory Test (BVMTR). The BICAMS has been validated in several English speaking and non-English speaking populations, and usefulness of the battery has been confirmed in several countries.

The objective of this study was to validate and assess the reliability of the Japanese version of the BICAMS in the Japanese population.

Methods

Patients with MS and healthy individuals

This study was conducted between March 2016 and May 2017 with 156 Japanese patients with MS (female/male = 107/49) diagnosed using the 2010 revised McDonald criteria and 126 age-, sex-, and education duration-matched Japanese healthy controls (female/male = 91/35) at nine sites (Sapporo Neurology Hospital, Kyushu University, Tokyo Women’s Medical University Yachiyo Medical Center, Saitama Medical Center, Osaka University Graduate School of Medicine, Chiba University, Tokyo Medical and Dental University, Tohoku Medical and Pharmaceutical University, and Hokkaido Medical Center), which cover major regions in Japan (Table 1). All patients underwent neurological examination, and those deemed to have visual or motor disabilities too severe to perform BICAMS were excluded. Patients with neuromyelitis optica spectrum disorders and patients with MS who had relapses and received steroids within one month before the examination were excluded from this study. Patients with MS who had history of major psychiatric disorders including depression preceding MS and received anti-psychotics were also excluded from this study. Patients were categorized according to MS subtype of disease course: one had primary progressive, 137 had relapsing–remitting and 18 had secondary progressive disease. Demographic and clinical data are shown in Table 1. Differences in sex ratio, duration of education, and age at examination between the patients and controls were not significant ($p > 0.05$). People with diseases of the CNS or major medical illnesses were excluded from the healthy control group. All participants had adequate vision, speech, and functions of upper extremities to complete testing based on clinician judgment. The study protocol was approved by the ethics committee of each participating site, and all patients and healthy controls gave their written informed consent to participate in the study.

BICAMS

The BICAMS battery includes three individual tests: the SDMT (faux example in Figure 1) for CPS, the first five recall trials of the CVLT2 (faux example in Figure 2) for auditory/verbal learning and memory, and the first three recall trials of the BVMTR (faux example in Figure 3) for visual/spatial memory. The BICAMS, which was originally written in English, was translated into Japanese and used for assessment of neuropsychological functions. Especially for the CVLT2, words were culturally adapted for the Japanese population, and the Japanese version of the CVLT2 has been recently validated. At baseline, original versions of the SDMT and the CVLT2 and Form 1 of the BVMTR were used.

The test battery was administered in the following fixed order: SDMT, first five trials of CVLT2, and first three recall trials of BVMTR.

Table 1. Demographic and clinical profiles for MS patients and controls

|                      | MS patients         | Controls                  |
|----------------------|---------------------|---------------------------|
| N (female/male)      | 156 (107/49)        | 126 (91/35)               |
| Age at examination (years) * (range) | 41.4 ± 9.3 (23–70) | 39.3 ± 11.9 (21–75)      |
| Education (years) * (range) | 14.1 ± 1.9 (12–22) | 14.3 ± 1.6 (12–18)       |
| Age at onset (years) * (range) | 31.0 ± 9.2 (10–64) |                           |
| Disease duration (years) * (range) | 10.3 ± 7.2 (0.7–39) |                           |
| EDSS * (range)       | 2.4 ± 2.0 (0–8)     |                           |
Subjects are asked to see a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper, and then, to answer the digit associated with each symbol as rapidly as possible for 90 s. Subjects are explained these procedures in Japanese like "上の段に符号、下の段に数字があり、それぞれの符号とその下の数字は対応しています。それぞれの数字にはそれぞれ異なった符号が割り当てられているので、90秒間に上段の符号に対応する数字を、一番上の符号と数字の対応表を見て、出来るだけ多く回答してください。"

Subjects are asked to listen to 16 words, and report as many of the items as possible. There is no instruction as to the order in which items are recalled. After recall is recorded, the entire list is read again followed by a second attempt at recall. Altogether, there are five learning trials. Subjects are explained these procedures in Japanese like "これから単語のリストを読み上げますのでよく聞いてください。読み終わったら、どんな順序でも構いませんので、リストにあった単語を出来るだけたくさん言ってください。これを5回繰り返します。"
Retest was performed at an interval ranging from one to three weeks as the paper for international validation recommends\(^\text{10}\) in 27 patients with MS and 30 controls among 156 patients with MS and 126 controls. For retest, alternate forms were employed (SDMT Alternate Form 1;\(^{26}\) CVLT2 Alternate Form; BVMTR Form 2) to reduce practice effects from prior exposure to the stimuli.

**Statistical analysis**

All data are expressed as mean ± standard deviation (SD). Statistical analysis was performed using the SAS 9.4 software package (SAS Institute Inc., Cary, NC, USA) and the GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA). Comparisons between groups were performed using paired-sample \(t\)-tests and the Mann–Whitney \(U\) test as appropriate. Measurements of the linear correlation between data sets were assessed using Pearson’s \(r\) coefficient. The international expert consensus committee recommended that a more valid measure of test–retest reliability is the Pearson correlation coefficient, and these \(r\) values for test–retest correlation were considered adequate if \(>0.70\) and good if \(>0.80.\(^{10}\) \(p\) values less than 0.05 were considered statistically significant.

**Results**

**BICAMS data in patients with MS and healthy controls**

Scores were uniformly lower in patients with MS than healthy controls (Table 2). Cohen’s \(d\) effect sizes were calculated. The SDMT had the highest Cohen’s \(d\) value (1.07), followed by BVMTR (0.67) (Table 2). Cronbach’s alpha coefficients for all three BICAMS test scores were 0.82 in patients with MS, 0.52 in the healthy control group and

|       | MS patients | Controls | \(p\)-value |
|-------|-------------|----------|-------------|
| **SDMT** |             |          |             |
| mean ± SD (range) | 47.9 ± 14.0 (2–84) | 61.0 ± 9.5 (29–89) | <0.0001 |
| Cohen’s \(d\) | 1.07 |          |             |
| Effect size \(r\) | 0.47 |          |             |
| **CVLT2** |             |          |             |
| mean ± SD (range) | 48.6 ± 12.6 (11–73) | 55.7 ± 10.5 (20–78) | <0.0001 |
| Cohen’s \(d\) | 0.60 |          |             |
| Effect size \(r\) | 0.29 |          |             |
| **BVMTR** |             |          |             |
| mean ± SD (range) | 23.5 ± 8.4 (0–36) | 28.3 ± 5.4 (12–36) | <0.0001 |
| Cohen’s \(d\) | 0.67 |          |             |
| Effect size \(r\) | 0.32 |          |             |

**Table 2.** BICAMS raw score in MS patients and controls

BICAMS: Brief International Cognitive Assessment for Multiple Sclerosis; MS: Multiple Sclerosis; SDMT: Symbol Digit Modalities Test; CVLT2: California Verbal Learning Test Second Edition; BVMTR: Brief Visuospatial Memory Test Revised. SD: standard deviation.
overall 0.79, suggesting an adequate level of within-construct reliability.

As expected, a significant negative correlation between age at examination and each BICAMS component was found in both patients with MS and controls (Table 3). Negative correlations between education level and the SDMT or the CVLT2 was found, although there were no correlations between education and the BVMTR in the control group (Table 3). On the other hand, in the MS patients group, no correlation was found between duration of education and each of the BICAMS tests (Table 3).

**Correlation between disease duration or EDSS and the BICAMS**

Negative correlations were found between disease duration and score in the SDMT and the BVMTR, although there was no association between disease duration and the CVLT2 (Table 4). As for disease severity and cognitive impairment, relatively strong negative correlations were found between the EDSS and scores of all three tests of the BICAMS in MS patients (Table 4).

**Tests–retest reliability**

Table 5 shows mean raw data of tests and retests in patients with MS and controls. As for correlation coefficients between the tests and the retests, the BVMTR in the control group was not so highly correlated \( r = 0.58 \) although the \( p \)-value was less than 0.001 (Table 5). The BVMTR overall had adequate correlation, and other data had good correlation over 0.80 (Table 5).

**Discussion**

Some degree of cognitive impairment is found in roughly half of the MS population, and diminished CPS and reduced learning on memory tasks are particularly common.\(^{27}\)

Previously, we reported on cognitive dysfunction in MS evaluated with the Brief Repeatable Battery of Neuropsychological tests (BRB-N), a historically well-established battery.\(^{28}\)

This battery takes around 45 min to administer,\(^{29}\) and requires considerable expertise, thus it is not well suited to routine clinic activity. On the other hand, it takes 15 min to administer the BICAMS battery, which is reliable and valid in many languages.\(^{9,10}\)

BICAMS has been shown to correlate well with the BRB-N (Kappa 0.46) and identify very similar numbers of MS patients as cognitively impaired.\(^{30}\)

Cultural background influences neuropsychological performance,\(^{31}\) and this battery has been validated in several countries including the Czech Republic,\(^{14}\) Italy,\(^{15}\) Hungary,\(^{16}\) Lithuania,\(^{17}\) Brazil,\(^{18}\) Ireland,\(^{19}\) Argentina\(^{20}\) and Greece.\(^{21}\) The present study meets an important clinical need in Japan, and we find that despite the marked

---

**Table 3. Correlation between age at examination or duration of education and the BICAMS**

|                  | Age at examination | Education duration |
|------------------|--------------------|--------------------|
|                  | MS patients        | Controls           |
|                  | \( r \)            | \( p \)-value      | MS patients | \( r \) | \( p \)-value | Controls | \( r \) | \( p \)-value |
| SDMT             | -0.37              | \(<0.0001\)        | -0.44       | \(<0.0001\) | 0.07    | n.s.     | 0.24     | \(<0.01\)    |
| CVLT2            | -0.25              | \(<0.01\)         | -0.23       | \(<0.01\)   | 0.13    | n.s.     | 0.25     | \(<0.05\)    |
| BVMTR            | -0.30              | \(<0.001\)        | -0.25       | \(<0.01\)   | 0.001   | n.s.     | 0.05     | n.s.        |

BICAMS: Brief International Cognitive Assessment for Multiple Sclerosis; MS: Multiple Sclerosis; SDMT: Symbol Digit Modalities Test; CVLT2: California Verbal Learning Test Second Edition; BVMTR: Brief Visuospatial Memory Test Revised. SD: standard deviation; n.s.: not significant \( (p > 0.05) \)

**Table 4. Correlation between disease duration or EDSS and the BICAMS**

|                  | Disease duration | EDSS               |
|------------------|------------------|--------------------|
|                  | \( r \)          | \( p \)-value      | \( r \) | \( p \)-value   |
| SDMT             | -0.30            | \(<0.001\)        | -0.56   | \(<0.0001\)    |
| CVLT2            | -0.12            | n.s.              | -0.29   | \(<0.001\)     |
| BVMTR            | -0.27            | \(<0.001\)        | -0.46   | \(<0.0001\)    |

EDSS: Expanded Disability Status Scale; BICAMS: Brief International Cognitive Assessment for Multiple Sclerosis; SDMT: Symbol Digit Modalities Test; CVLT2: California Verbal Learning Test Second Edition; BVMTR: Brief Visuospatial Memory Test Revised. SD: standard deviation; n.s.: not significant \( (p > 0.05) \)
Table 5. Test–retest reliability of the BICAMS tests in MS patients and controls

|           | Overall |       |       | Overall |       |       |
|-----------|---------|-------|-------|---------|-------|-------|
|           | test    | retest| r/p-value | test    | retest| r/p-value |
| SDMT      | 53.1 ± 13.8 | 55.0 ± 15.3 | 0.93/ <0.0001 | 45.1 ± 13.2 | 47.3 ± 15.9 | 0.94/ <0.0001 |
|           | (16–80) | (12–79) |       | (16–66) | (12–76) |       |
| CVLT2     | 50.3 ± 12.9 | 54.7 ± 11.3 | 0.82/ <0.0001 | 48.6 ± 13.1 | 52.4 ± 11.6 | 0.80/ <0.0001 |
|           | (11–73) | (23–77) |       | (11–73) | (23–69) |       |
| BVMTR     | 27.5 ± 6.3 | 29.8 ± 4.5 | 0.77/ <0.0001 | 25.5 ± 7.6 | 28.6 ± 5.4 | 0.82/ <0.0001 |
|           | (2–36)  | (8–36) |       | (2–34)  | (8–36) |       |

BICAMS: Brief International Cognitive Assessment for Multiple Sclerosis; MS: Multiple Sclerosis; SDMT: Symbol Digit Modalities Test; CVLT2: California Verbal Learning Test Second Edition; BVMTR: Brief Visuospatial Memory Test Revised. SD: standard deviation. For each test, raw data are expressed as mean ± standard deviation scores (ranges).

There are some limitations in this study, including application to patients with visual impairments and the cross-sectional nature of the study. Subjects with major psychiatric disorders were excluded from this study. However, in this study, detailed psychiatric investigations with some batteries such as Beck Depression Inventory Second Edition (BDI-II) were not done, and minor psychiatric conditions might have affected some cognitive functions. Future studies will reveal the association between depressive state and data of BICAMS in the Japanese population. In fact, in this study, patients who had visual or hand disabilities too severe to perform BICAMS were excluded. Our current study provides data for the Japanese BICAMS in 126 healthy controls, and whilst this does not constitute a full normative sample for the population as a whole, it is matched to the demographics of the main MS population and is sufficient to address the key questions of test validity central to this paper. As presented in the consensus panel BICAMS papers, the purpose of the increasing number of small-scale country/language validations is to provide a normative sample exclusively for MS clinic patients. The lack of 17–20-year-old healthy subjects in this study could hamper efforts to developed regression-based norms that depend on adequate sampling of all ages. We again find that the BICAMS measures are influenced by variables such as age, sex, and level of education. Importantly, the rank order of these correlations was as expected, with CPS being most strongly related to age and verbal memory most strongly related to education. We (Benedict, Langdon, Niino) are planning to extend the normalization process and integrate these data with norms from other countries to further our endeavor to provide international regression-based norms for clinical use.

As for disease duration and scores on the BICAMS tests, negative associations were found in the SDMT and the BVMTR, but not in the CVLT2. In our previous study with the BRB-N, a negative association was demonstrated between disease duration and verbal memory evaluated by a selective reminding test. The battery for verbal memory in this study was different from the battery in our previous study, and that may be one of the reasons for the different result. As for other reasons, the included patients were different between the two studies. In fact, there is a study that demonstrated negative associations between disease duration and the BICAMS scores of all three tests. Previous studies, including our study, demonstrated that cognitive impairment evaluated by batteries such as the BRB-N had correlations with physical disability as evaluated by EDSS. Our current data also demonstrated similar findings.

The international expert consensus committee reported that test–retest reliability has high priority and is very relevant for the validation of BICAMS. Regarding this issue, we assessed about 60 participants including patients and controls to undergo retest within 1–3 weeks post baseline. In the retest, an alternative version of each test was used. As a result, strong correlations have been established with assessing the test–retest reliability in all tests other than the BVMTR in controls. Our study confirmed good test–retest reliability. The controls’
performance shows slightly weaker test–retest correlation in the BVMTR in controls in our study. On the other hand, Sandi et al. reported a slightly weaker correlation in the CVLT2.16 The difference might be due to the included participants or cultural background.

Consistent with prior research, our data reveal the largest effects and best reliability for the SDMT in support of our previous results.26 The SDMT could provide a better index of CPS, which seems to be more frequently impaired in patients with MS, and the SDMT is the best psychometric measure available for assessing CPS in patients with MS.34,35 Further, the SDMT is a good test to predict cognitive impairment in patients with MS, even in the early stages of the disease.36

In summary, the BICAMS is a useful battery to screen cognitive impairment in patients with MS, and international validation for BICAMS has been done. The study provides validation of Japanese version of the BICAMS, the first project in Asia, and confirms that this battery can be useful for clinical practice in Japanese patients with MS. Nationality significantly influences BICAMS performance, hence the importance of the inclusion of a nationality variable when international norms for the BICAMS are constructed.37 It is important to investigate the potential impact of nationality on international validation in the future.

Acknowledgements

We thank Dr Tomiki Sumiiyoshi, Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry for his great help and suggestions with the Japanese version of CVLT2. We also thank Ms Eri Sato at Sapporo Neurology Hospital, Ms Yumi Kon at Hokkaido Medical Center, Dr Koji Shinoda at Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Dr Yuji Nakatsuji at Department of Neurology, Toyama University Hospital, and Dr Takanori Yokota at Department of Neurology and Neurological Science, Tokyo Medical and Dental University for their great help with this study.

Conflicts of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan.

References

1. Filippi M. MRI measures of neurodegeneration in multiple sclerosis: Implications for disability, disease monitoring, and treatment. J Neurol 2015; 262: 1–6.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452.
3. Sepulcre J, Vanotti S, Hernández R, et al. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult Scler 2006; 12: 187–195.
4. Huijbregts SC, Kalkers NF, de Sonneville LM, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004; 63: 335–339.
5. Solari A, Mancuso L, Motta A, et al. Comparison of two brief neuropsychological batteries in people with multiple sclerosis. Mult Scler 2002; 8: 169–176.
6. Saccà F, Costabile T, Carotenuto A, et al. The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests. Mult Scler 2017; 23: 1289–1296.
7. Bobholz JA and Rao SM. Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol 2003; 16: 283–288.
8. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: A consensus approach. Clin Neuropsychol 2002; 16: 381–397.
9. Langdon DW, Amato MP, Boringa J, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 2012; 18: 891–898.
10. Benedict RH, Amato MP, Boringa J, et al. Brief International Cognitive Assessment for MS (BICAMS): International standards for validation. BMC Neurol 2012; 12: 55.
11. Smith A. Symbol digit modalities test: Manual. Los Angeles: Western Psychological Services, 1982.
12. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test Manual: Second Edition, Adult Version, San Antonio, TX: Psychological Corporation, 2000.
13. Benedict RH. Brief Visuospatial Memory Test – Revised: Professional Manual, Odessa, Floriday: Psychological Assessment Resources, Inc. 1997.
14. Dusankova JB, Kalincik T, Havrova E, et al. Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Clin Neuropsychol 2012; 26: 1186–1200.
15. Goretti B, Niccolai C, Hakiki B, et al. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Normative values with gender, age and education corrections in the Italian population. *BMC Neurol* 2014; 14: 171.

16. Sandi D, Rudisch T, Füvesi J, et al. The Hungarian validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery and the correlation of cognitive impairment with fatigue and quality of life. *Mult Scler Relat Disord* 2015; 4: 499–504.

17. Giedraitienė N, Kizlaitienė R and Kaubrys G. The BICAMS Battery for assessment of Lithuanian-speaking multiple sclerosis patients: Relationship with age, education, disease disability, and duration. *Med Sci Monit* 2015; 21: 3853–3859.

18. Spedo CT, Frndak SE, Marques VD, et al. Cross-cultural adaptation, reliability, and validity of the BICAMS in Brazil. *Clin Neuropsychol* 2015; 29: 836–846.

19. O’Connell K, Langdon D, Tubridy N, et al. A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS). *Mult Scler Relat Disord* 2015; 4: 521–525.

20. Vanotti S, Smerbeck A, Benedict RH, et al. A new assessment tool for patients with multiple sclerosis from Spanish-speaking countries: Validation of the Brief International Cognitive Assessment for MS (BICAMS) in Argentina. *Clin Neuropsychol* 2016; 30: 1023–1031.

21. Polychroniadou E, Bakirtzis C, Langdon D, et al. Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in Greek population with multiple sclerosis. *Mult Scler Relat Disord* 2016; 9: 68–72.

22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011; 69: 292–302.

23. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. *Lancet Neurol* 2007; 6: 805–815.

24. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. *Neurology* 2014; 83: 278–286.

25. Sumiyoshi T, Toyomaki A, Kawano N, et al. Reliability and validity of the California Verbal Learning Test-II - Japanese version. *Psychiatry Clin Neurosci* 2017; 71: 417–418.

26. Benedict RH, Smerbeck A, Parikh R, et al. Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: Implications for multiple sclerosis clinical trials. *Mult Scler* 2012; 18: 1320–1325.

27. Benedict RH and Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. *Nat Rev Neurol* 2011; 7: 332–342.

28. Niino M, Mifune N, Kojiriyama T, et al. Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis. *BMC Neurol* 2014; 14: 3.

29. Niino M. Neuropsychological Aspects of Multiple Sclerosis, In: Kusunoki S (ed) *Neuroimmunological Diseases*. Berlin: Springer-Verlag GmbH, 2016, pp. 123–133.

30. Nisbett RE, Peng K, Choi I. Culture and systems of thought: Holistic versus analytic cognition. *Psychol Rev* 2001; 108: 291–310.

31. Polychroniadou E, Bakirtzis C, Langdon D, et al. A comparison of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS). *Mult Scler Relat Disord* 2015; 4: 521–525.

32. Boringa JB, Lazeron RH, Reuling IE, et al. The Brief Repeatable Battery of Neuropsychological Tests: Normative values allow application in multiple sclerosis clinical practice. *Mult Scler* 2001; 7: 263–267.

33. Amato MP, Portaccio E, Garetti B, et al. The Rao’s Brief Repeatable Battery and Stroop Test: Normative values with age, education and gender corrections in an Italian population. *Mult Scler* 2006; 12: 787–793.

34. Forn C, Belenguer A, Parcet-Ibars MA, et al. Information-processing speed is the primary deficit underlying the poor performance of multiple sclerosis patients in the Paced Auditory Serial Addition Test (PASAT). *J Clin Exp Neuropsychol* 2008; 30: 789–796.

35. Benedict RH, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. *Mult Scler* 2017; 23: 721–733.

36. Deloire MS, Bonnet MC, Salort E, et al. How to detect cognitive dysfunction at early stages of multiple sclerosis? *Mult Scler* 2006; 12: 445–452.

37. Smerbeck A, Benedict RHB, Eshaghi A, et al. Influence of nationality on the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). *Clin Neuropsychol* 2017 Jul 19: 1–9.